The National Alliance of Advocates
for Buprenorphine Treatment
Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2
Info for Treatment Providers:
Information regarding buprenorphine treatment, addiction and other related topics for Physicians, Therapists/Counselors and Pharmacists.
Adobe Acrobat Viewer is required to view Adobe Acrobat (PDF) files.
If you don't have Acrobat Viewer already installed, click here to download it now.
Up-to-date Patient/Physician
Matching System Statistics
Since the national launch of the Patient Physician Matching System on September 1, 2006, to 04/11/2021 there have been 81097 patients contacted by at least one of the 4258 participating physicians. There are currently 0 patients in the system that are currently seeking a physician.
Learn about the Patient/Physician Matching System – PPMS
Maps (Patients | Physicians) | Provider Registration
Physicians
TreatmentMatch.org Patient/Physician Matching System
SAMHSA Physician Locator (add, delete, edit)
If not already listed, DATA-2000 waived physicians may call 1-866-BUP-CSAT (1-866-287-2728) or e-mail info@buprenorphine.samhsa.gov with requests to be added to the Locator. See current locator listing at: www.naabt.org/local
The DEA must also be notified when a waived physician changes the primary practice address at which they intend to treat opioid addiction under the authority of their DATA 2000 waiver. Call the DEA Office of Diversion Control at 1-800-882-9539. Phone numbers for local DEA offices can be found on the DEA Web site at http://www.dea.gov.
Substance Abuse and Mental Health Services Administration (SAMHSA) website
Physician Certification
Physician Buprenorphine Certification Events – both live and online.
BupPractice.com - American Society of Addiction Medicine (ASAM) online certification training.
American Academy of Addiction Psychiatry (AAAP) online certification training.
Most popular physician downloads.
Physician and Pharmacist Frequently Asked Questions.
NEW Blank "intent" form to treat up to 100 patients--fax to 240-276-1630
TIP 40 PDF (Clinical Guidelines for the Use of Buprenorphine) More TIPs on literature page
The 3 day rule (dispensing buprenorphine without a waiver)
DEA Articulates Policy on the Use of Buprenorphine for Pain- Letter to Dr. Heit
Other DEA regulations cleared up
Suboxone Film Package insert, prescribing information (PI)
Preventing Precipitated Withdrawal / COWS
How Buprenorphine Works--Receptor sheet
Please see our literature page for more downloads.
Therapists & Counselors
Evidence-Based Counselor/Therapist Locator
Sign up: To be on the naabt.org Evidence-Based Counselor/Therapist Locator; to receive a free Resource Kit; to receive our free newsletter.
Buprenorphine resource locator (see your listing)
TreatmentMatch.org Patient/Physician Matching System
What is the Patient/Physician Matching System?
Patient Registration. Register your patients on the PPMS to help locate a certified buprenorphine-prescribing physician.
Patient Online Support Community.
In some areas patients are unable to find a “medication friendly” support group. These patients may benefit from online patient peer support in conjunction with one-on-one therapy. Patients can participate 24/7 in the online buprenorphine community at: http://www.naabt.org/forum
Popular downloads.
June 2006 NAABT newsletter: Counseling and Buprenorphine
TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
This Treatment Improvement Protocol (TIP), Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus - and evidence -based treatment guidance for the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide physicians with information they can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. These guidelines address the pharmacology and physiology of opioids, opioid addiction, and treatment with buprenorphine; describe patient assessment and the choice of opioid addiction treatment options; provide detailed treatment protocols for opioid withdrawal and maintenance therapy with buprenorphine; and include information on the treatment of special populations, e.g., pregnant women, adolescents, and polysubstance users. This TIP represents another step by the Center for Substance Abuse Treatment (CSAT) toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States.
http://www.naabt.org/documents/TIP40PDF.pdf
TIP 47: Substance Abuse: Clinical Issues in Intensive Outpatient Treatment
This Treatment Improvement Protocol (TIP), Substance Abuse: Clinical Issues in Intensive Outpatient Treatment, addresses the practical needs of treatment providers as they design and implement IOT programs. The TIP provides specific information on the principles of intensive outpatient treatment; services and treatment models; modifications for distinct population groups; culturally competent treatment; screening and patient placement criteria; counseling methods and techniques, including involvement of families; and the continuum of care. The TIP also covers such important issues as how to improve early retention, provide the appropriate length and intensity of services, provide the most promising mix of wrap-around services for positive client outcomes, and arrange ongoing care in the community.
http://download.ncadi.samhsa.gov/prevline/pdfs/TIP_47.pdf
TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
Opioid addiction is a problem with high costs to individuals, families, and society. This TIP provides a detailed description of medication-assisted treatment for opioid addiction, including optional approaches such as comprehensive maintenance treatment, detoxification, and medically supervised withdrawal.
http://download.ncadi.samhsa.gov/Prevline/pdfs/bkd524.pdfCompanion Kap Keys
http://kap.samhsa.gov/products/tools/keys/pdfs/KK_43.pdf
TIP 44: Substance Abuse Treatment for Adults in the Criminal Justice System
Research consistently demonstrates a strong connection between criminal activity and substance abuse; research also finds that involvement in substance abuse treatment reduces recidivism for offenders who use drugs. This TIP presents clinical guidelines to assist counselors in dealing with problems that routinely arise because of their clients’ status in the criminal justice system.
http://download.ncadi.samhsa.gov/Prevline/pdfs/bkd526.pdf
TIP 39: Substance Abuse Treatment & Family Therapy
This best-practice guideline for the treatment of substance use disorders focuses on how substance abuse affects the entire family and how substance abuse treatment providers can use principles from family therapy to change the interactions among family members.
http://download.ncadi.samhsa.gov/prevline/pdfs/bkd504.pdf
TIP 42: Substance Abuse Treatment for Persons With Co-Occurring Disorders
This TIP identifies key elements of programming for co-occurring disorders in substance abuse treatment agencies. The elements described have relevance for mental health agencies and other service systems that seek to coordinate mental health and substance abuse services for their clients who need both.
http://download.ncadi.samhsa.gov/prevline/pdfs/bkd515.pdf
TIP 37: Substance Abuse Treatment for Persons With HIV/AIDS
This installment of the Treatment Improvement Protocol (TIP) Series discusses the unique substance abuse treatment needs of a person with HIV/AIDS. Topics covered include a general overview of HIV/AIDS, medical treatment, mental health treatment, primary and secondary modes of HIV prevention, and many other pertinent issues.
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.64746
TIP 35: Enhancing Motivation for Change in Substance Use Disorder Treatment
This TIP shows how substance abuse treatment staff can influence change by developing a therapeutic relationship that respects and builds on the client’s autonomy and, at the same time, makes the treatment clinician a partner in the change process.
http://download.ncadi.samhsa.gov/Prevline/pdfs/SMA06-4190.pdf
The 3 day rule (dispensing buprenorphine without a waiver)
DEA Articulates Policy on the Use of Buprenorphine for Pain- Letter to Dr. Heit
Other DEA regulations cleared up
Suboxone/Subutex Package insert, prescribing information (PI)
Preventing Precipitated Withdrawal / COWS
How Buprenorphine Works--Receptor sheet
Please see our literature page for more downloads.
Pharmacists
Buprenorphine-Stocking
Pharmacy Locator
Sign up: To be on the naabt.org Buprenorphine-Stocking Pharmacy Locator; to receive a free counter display; to receive our free newsletter.
TreatmentMatch.org Patient/Physician Matching System
Patient Online Support Community.
In some areas patients are unable to find a “medication friendly” support group. These patients may benefit from online patient peer support. Patients can participate 24/7 in the online buprenorphine community at here.
Popular downloads.
TIP 40 PDF (Clinical Guidelines for the Use of Buprenorphine) More TIPs on literature page
The 3 day rule (dispensing buprenorphine without a waiver)
DEA Articulates Policy on the Use of Buprenorphine for Pain- Letter to Dr. Heit
Other DEA regulations cleared up
Suboxone/Subutex Package insert, prescribing information (PI)
Preventing Precipitated Withdrawal / COWS
How Buprenorphine Works--Receptor sheet
Please see our literature page for more downloads.
Nurses
TreatmentMatch.org Patient/Physician Matching System
SAMHSA Physician Locator (add, delete, edit)
If not already listed, DATA-2000 waived physicians may call 1-866-BUP-CSAT (1-866-287-2728) or e-mail info@buprenorphine.samhsa.gov with requests to be added to the Locator. See current locator listing at: www.naabt.org/local
The DEA must also be notified when a waived physician changes the primary practice address at which they intend to treat opioid addiction under the authority of their DATA 2000 waiver. Call the DEA Office of Diversion Control at 1-800-882-9539. Phone numbers for local DEA offices can be found on the DEA Web site at http://www.dea.gov.
Substance Abuse and Mental Health Services Administration (SAMHSA) website
Most popular physician downloads.
June 2006 NAABT newsletter: Counseling and Buprenorphine
TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
This Treatment Improvement Protocol (TIP), Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus - and evidence -based treatment guidance for the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide physicians with information they can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. These guidelines address the pharmacology and physiology of opioids, opioid addiction, and treatment with buprenorphine; describe patient assessment and the choice of opioid addiction treatment options; provide detailed treatment protocols for opioid withdrawal and maintenance therapy with buprenorphine; and include information on the treatment of special populations, e.g., pregnant women, adolescents, and polysubstance users. This TIP represents another step by the Center for Substance Abuse Treatment (CSAT) toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States.
http://www.naabt.org/documents/TIP40PDF.pdf
TIP 47: Substance Abuse: Clinical Issues in Intensive Outpatient Treatment
This Treatment Improvement Protocol (TIP), Substance Abuse: Clinical Issues in Intensive Outpatient Treatment, addresses the practical needs of treatment providers as they design and implement IOT programs. The TIP provides specific information on the principles of intensive outpatient treatment; services and treatment models; modifications for distinct population groups; culturally competent treatment; screening and patient placement criteria; counseling methods and techniques, including involvement of families; and the continuum of care. The TIP also covers such important issues as how to improve early retention, provide the appropriate length and intensity of services, provide the most promising mix of wrap-around services for positive client outcomes, and arrange ongoing care in the community.
http://download.ncadi.samhsa.gov/prevline/pdfs/TIP_47.pdf
TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
Opioid addiction is a problem with high costs to individuals, families, and society. This TIP provides a detailed description of medication-assisted treatment for opioid addiction, including optional approaches such as comprehensive maintenance treatment, detoxification, and medically supervised withdrawal.
http://download.ncadi.samhsa.gov/Prevline/pdfs/bkd524.pdfCompanion Kap Keys
http://kap.samhsa.gov/products/tools/keys/pdfs/KK_43.pdf
TIP 44: Substance Abuse Treatment for Adults in the Criminal Justice System
Research consistently demonstrates a strong connection between criminal activity and substance abuse; research also finds that involvement in substance abuse treatment reduces recidivism for offenders who use drugs. This TIP presents clinical guidelines to assist counselors in dealing with problems that routinely arise because of their clients’ status in the criminal justice system.
http://download.ncadi.samhsa.gov/Prevline/pdfs/bkd526.pdf
TIP 39: Substance Abuse Treatment & Family Therapy
This best-practice guideline for the treatment of substance use disorders focuses on how substance abuse affects the entire family and how substance abuse treatment providers can use principles from family therapy to change the interactions among family members.
http://download.ncadi.samhsa.gov/prevline/pdfs/bkd504.pdf
TIP 42: Substance Abuse Treatment for Persons With Co-Occurring Disorders
This TIP identifies key elements of programming for co-occurring disorders in substance abuse treatment agencies. The elements described have relevance for mental health agencies and other service systems that seek to coordinate mental health and substance abuse services for their clients who need both.
http://download.ncadi.samhsa.gov/prevline/pdfs/bkd515.pdf
TIP 37: Substance Abuse Treatment for Persons With HIV/AIDS
This installment of the Treatment Improvement Protocol (TIP) Series discusses the unique substance abuse treatment needs of a person with HIV/AIDS. Topics covered include a general overview of HIV/AIDS, medical treatment, mental health treatment, primary and secondary modes of HIV prevention, and many other pertinent issues.
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.64746
TIP 35: Enhancing Motivation for Change in Substance Use Disorder Treatment
This TIP shows how substance abuse treatment staff can influence change by developing a therapeutic relationship that respects and builds on the client’s autonomy and, at the same time, makes the treatment clinician a partner in the change process.
http://download.ncadi.samhsa.gov/Prevline/pdfs/SMA06-4190.pdf
The 3 day rule (dispensing buprenorphine without a waiver)
DEA Articulates Policy on the Use of Buprenorphine for Pain- Letter to Dr. Heit
Other DEA regulations cleared up
Suboxone/Subutex Package insert, prescribing information (PI)
Preventing Precipitated Withdrawal / COWS
How Buprenorphine Works--Receptor sheet
Please see our literature page for more downloads.
The Purpose of Buprenorphine Treatment:
To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -
The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:
- Educate the public about the disease of opioid addiction and the buprenorphine treatment option.
- Help reduce the stigma and discrimination associated with patients with addiction disorders.
- Serve as a conduit connecting patients in need of treatment to buprenorphine treatment providers.
- U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
- Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
- Subutex Discontinued in the US market in late 2011.
- Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
- Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
- Probuphine FDA approved 5/26/2016 - FDA Probuphine press release